Uniqure NV (NASDAQ:QURE) Position Boosted by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale boosted its position in Uniqure NV (NASDAQ:QURE) by 21.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,300 shares of the biotechnology company’s stock after buying an additional 2,200 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Uniqure were worth $520,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. 683 Capital Management LLC raised its holdings in shares of Uniqure by 10.3% during the fourth quarter. 683 Capital Management LLC now owns 1,085,000 shares of the biotechnology company’s stock valued at $31,270,000 after purchasing an additional 100,900 shares during the period. RTW Investments LP raised its holdings in shares of Uniqure by 7.7% during the fourth quarter. RTW Investments LP now owns 461,837 shares of the biotechnology company’s stock valued at $13,310,000 after purchasing an additional 32,857 shares during the period. Sphera Funds Management LTD. raised its holdings in shares of Uniqure by 30.9% during the fourth quarter. Sphera Funds Management LTD. now owns 232,849 shares of the biotechnology company’s stock valued at $6,711,000 after purchasing an additional 55,000 shares during the period. Lord Abbett & CO. LLC raised its holdings in shares of Uniqure by 2.5% during the fourth quarter. Lord Abbett & CO. LLC now owns 151,271 shares of the biotechnology company’s stock valued at $4,359,000 after purchasing an additional 3,682 shares during the period. Finally, Vanguard Group Inc raised its holdings in shares of Uniqure by 4.1% during the third quarter. Vanguard Group Inc now owns 101,992 shares of the biotechnology company’s stock valued at $3,712,000 after purchasing an additional 3,992 shares during the period. Institutional investors and hedge funds own 60.12% of the company’s stock.

In other news, Director Philip Astley-Sparke sold 6,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $63.63, for a total transaction of $381,780.00. Following the completion of the transaction, the director now directly owns 18,872 shares of the company’s stock, valued at approximately $1,200,825.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christian Klemt sold 1,546 shares of the stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $57.18, for a total transaction of $88,400.28. Following the transaction, the insider now directly owns 54,539 shares of the company’s stock, valued at $3,118,540.02. The disclosure for this sale can be found here. Insiders sold a total of 21,546 shares of company stock valued at $1,296,260 over the last ninety days. 2.91% of the stock is currently owned by insiders.

Several brokerages have recently weighed in on QURE. BidaskClub upgraded shares of Uniqure from a “sell” rating to a “hold” rating in a report on Tuesday, May 21st. Janney Montgomery Scott reiterated a “buy” rating on shares of Uniqure in a report on Tuesday. SunTrust Banks upped their price objective on shares of Uniqure to $76.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Robert W. Baird assumed coverage on shares of Uniqure in a research report on Thursday, March 28th. They set an “outperform” rating and a $85.00 target price for the company. Finally, Piper Jaffray Companies assumed coverage on shares of Uniqure in a research report on Friday, April 12th. They set an “overweight” rating and a $80.00 target price for the company. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $75.82.

Shares of QURE stock opened at $69.91 on Thursday. Uniqure NV has a 52-week low of $21.98 and a 52-week high of $78.02. The company has a quick ratio of 9.51, a current ratio of 9.51 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $2.64 billion, a price-to-earnings ratio of -29.88 and a beta of 0.95.

Uniqure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.03). Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. The firm had revenue of $1.14 million during the quarter, compared to the consensus estimate of $2.00 million. On average, equities analysts expect that Uniqure NV will post -3.01 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Uniqure NV (NASDAQ:QURE) Position Boosted by DekaBank Deutsche Girozentrale” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2019/06/13/uniqure-nv-nasdaqqure-position-boosted-by-dekabank-deutsche-girozentrale.html.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Featured Story: What is the return on assets formula?

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).

Institutional Ownership by Quarter for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.